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Abstract 
Introduction: Smoking is a major cause of disease burden and reduced quality of life for people with 
severe mental illness (SMI). It places significant resource pressure on health systems and financial stress 
on smokers with SMI (SSMI). Telephone-based smoking cessation interventions have been shown to be 
cost effective in general populations. However, evidence suggests that SSMI are less likely to be referred 
to quitlines, and little is known about the effectiveness and cost effectiveness of such interventions that 
specifically target SSMI. The Quitlink randomized controlled trial for accessible smoking cessation 
support for SSMI aims to bridge this gap. This paper describes the protocol for evaluating the cost 
effectiveness of Quitlink. 
Methods: Quitlink will be implemented in the Australian setting, utilizing the existing mental health peer 
workforce to link SSMI to a tailored quitline service. The effectiveness of Quitlink will be evaluated in a 
clustered randomized controlled trial. A cost-effectiveness evaluation will be conducted alongside the 
Quitlink clustered randomized controlled trial (RCT) with incremental cost-effectiveness ratios (ICERs) 
calculated for the cost (AUD) per successful quit and quality adjusted life year (QALY) gained at 8 months 
compared with usual care from both health care system and limited societal perspectives. Financial 
implications for study participants will also be investigated. A modeled cost-effectiveness analysis will 
also be conducted to estimate future costs and benefits associated with any treatment effect observed 
during the trial. Results will be extrapolated to estimate the cost effectiveness of rolling out Quitlink 
nationally. Sensitivity analyses will be undertaken to assess the impact on results from plausible 
variations in all modeled variables. 
Discussion: SSMI require additional support to quit. Quitlink utilizes existing peer worker and quitline 
workforces and tailors quitline support specifically to provide that increased cessation support. Given 
Quitlink engages these existing skilled workforces, it is hypothesized that, if found to be effective, it will 
also be found to be both cost effective and scalable. This protocol describes the economic evaluation of 
Quitlink that will assess these hypotheses. 
Ethics and dissemination: Full ethics clearances have been received for the methods described below 
from the University of Newcastle (Australia) Human Research Ethics Committee (H-2018-0192) and St 
Vincent's Hospital, Melbourne (HREC/18/SVHM/154). The trial has been registered with the Australian 
and New Zealand Clinical Trials Registry (ACTRN12619000244101). Participant consent is sought both to 
participate in the study and to have the study data linked to routine health administrative data on publicly 
subsidized health service and pharmaceutical use, specifically the Medicare Benefits and Pharmaceutical 
Benefits Schemes (MBS/PBS). Trial findings (including economic evaluation) will be published in peer 
reviewed journals and presented at international conferences. Collected data and analyses will be made 
available in accordance with journal policies and study ethics approvals. Results will be presented to 
relevant government authorities with an interest in cost effectiveness of these types of interventions. 
Disciplines 
Education | Social and Behavioral Sciences 
Publication Details 
Sweeney, R., Moodie, M., Baker, A. L., Borland, R., Castle, D., Segan, C., Turner, A., Attia, J., Kelly, P. J., 
Brophy, L., Bonevski, B., Williams, J. M., Baird, D., White, S. L. & McCarter, K. (2019). Protocol for an 
Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation 
Support for People With Severe Mental Illness. Frontiers In Psychiatry, 10 618-1-618-10. 
Authors 
Rohan Sweeney, Marj Moodie, Amanda Baker, Ron Borland, David J. Castle, Catherine Segan, Alyna Turner, 
John R. Attia, Peter James Kelly, Lisa Brophy, Billie Bonevski, Jill Williams, Donita Baird, Sarah L. White, 
and Kristen McCarter 
This journal article is available at Research Online: https://ro.uow.edu.au/sspapers/4496 
1 September 2019 | Volume 10 | Article 618Frontiers in Psychiatry | www.frontiersin.org
CLINICAL STUDY PROTOCOL
doi: 10.3389/fpsyt.2019.00618
published: 03 September 2019
Edited by: 
Błażej Misiak, 
Wroclaw Medical University, Poland
Reviewed by: 
Kim Dalziel, 
The University of Melbourne, Australia 
Ernest Marek Tyburski, 
University of Szczecin, Poland
*Correspondence: 
Rohan Sweeney 
rohan.sweeney@monash.edu.au
Specialty section: 
This article was submitted to 
Schizophrenia, 
a section of the journal 
Frontiers in Psychiatry
Received: 31 August 2018
Accepted: 01 August 2019
Published: 03 September 2019
Citation: 
Sweeney R, Moodie M, Baker AL, 
Borland R, Castle D, Segan C, 
Turner A, Attia J, Kelly PJ, Brophy L, 
Bonevski B, Williams JM, Baird D, 
White SL and McCarter K (2019) 
Protocol for an Economic Evaluation 
of the Quitlink Randomized Controlled 
Trial for Accessible Smoking 
Cessation Support for People With 
Severe Mental Illness. 
Front. Psychiatry 10:618. 
doi: 10.3389/fpsyt.2019.00618
Protocol for an Economic Evaluation 
of the Quitlink Randomized 
Controlled Trial for Accessible 
Smoking Cessation Support for 
People With Severe Mental Illness
Rohan Sweeney 1*, Marj Moodie 2, Amanda L. Baker 3, Ron Borland 4,5, David Castle 6,7, 
Catherine Segan 4,8, Alyna Turner 9,10, John Attia 3, Peter J. Kelly 11, Lisa Brophy 8,12, 
Billie Bonevski 3, Jill M. Williams 13, Donita Baird 3, Sarah L. White 4 and Kristen McCarter 3
1 Centre for Health Economics, Monash Business School, Monash University, Melbourne, VIC, Australia, 2 Deakin Health 
Economics, Centre for Population Health Research, Deakin University, Geelong, VIC, Australia, 3 Faculty of Health and 
Medicine, University of Newcastle, Newcastle, NSW, Australia, 4 The Cancer Council Victoria, Melbourne, VIC, Australia, 
5 School of Psychological Sciences, University of Melbourne, Melbourne, VIC, Australian 6 Department of Psychiatry, University 
of Melbourne, Melbourne, VIC, Australia, 7 Department of Psychiatry, St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia, 
8 Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia, 9 IMPACT Strategic 
Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia, 10 Barwon Health, Geelong, VIC, Australia,  
11 Illawarra Institute for Mental Health, School of Psychology, University of Wollongong, Wollongong, NSW, Australia,  
12 Mind Australia, Melbourne, VIC, Australia, 13 Division of Addiction Psychiatry, Rutgers Robert Wood Johnson Medical School 
and Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States
Introduction: Smoking is a major cause of disease burden and reduced quality of life for 
people with severe mental illness (SMI). It places significant resource pressure on health 
systems and financial stress on smokers with SMI (SSMI). Telephone-based smoking 
cessation interventions have been shown to be cost effective in general populations. 
However, evidence suggests that SSMI are less likely to be referred to quitlines, and 
little is known about the effectiveness and cost effectiveness of such interventions that 
specifically target SSMI. The Quitlink randomized controlled trial for accessible smoking 
cessation support for SSMI aims to bridge this gap. This paper describes the protocol for 
evaluating the cost effectiveness of Quitlink.
Methods: Quitlink will be implemented in the Australian setting, utilizing the existing 
mental health peer workforce to link SSMI to a tailored quitline service. The effectiveness 
of Quitlink will be evaluated in a clustered randomized controlled trial. A cost-effectiveness 
evaluation will be conducted alongside the Quitlink clustered randomized controlled trial 
(RCT) with incremental cost-effectiveness ratios (ICERs) calculated for the cost (AUD) 
per successful quit and quality adjusted life year (QALY) gained at 8 months compared 
with usual care from both health care system and limited societal perspectives. Financial 
implications for study participants will also be investigated. A modeled cost-effectiveness 
analysis will also be conducted to estimate future costs and benefits associated with any 
treatment effect observed during the trial. Results will be extrapolated to estimate the cost 
effectiveness of rolling out Quitlink nationally. Sensitivity analyses will be undertaken to 
assess the impact on results from plausible variations in all modeled variables.
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Discussion: SSMI require additional support to quit. Quitlink utilizes existing peer 
worker and quitline workforces and tailors quitline support specifically to provide that 
increased cessation support. Given Quitlink engages these existing skilled workforces, it 
is hypothesized that, if found to be effective, it will also be found to be both cost effective 
and scalable. This protocol describes the economic evaluation of Quitlink that will assess 
these hypotheses.
Ethics and dissemination: Full ethics clearances have been received for the methods 
described below from the University of Newcastle (Australia) Human Research Ethics 
Committee (H-2018-0192) and St Vincent’s Hospital, Melbourne (HREC/18/SVHM/154). 
The trial has been registered with the Australian and New Zealand Clinical Trials Registry 
(ACTRN12619000244101). Participant consent is sought both to participate in the 
study and to have the study data linked to routine health administrative data on publicly 
subsidized health service and pharmaceutical use, specifically the Medicare Benefits 
and Pharmaceutical Benefits Schemes (MBS/PBS). Trial findings (including economic 
evaluation) will be published in peer reviewed journals and presented at international 
conferences. Collected data and analyses will be made available in accordance with journal 
policies and study ethics approvals. Results will be presented to relevant government 
authorities with an interest in cost effectiveness of these types of interventions.
Keywords: smoking, smoking cessation, mental illness, quitline, peer worker, economic evaluation, 
cost-effectiveness
INTRODUCTION
While smoking rates have declined in many countries, the rate 
of decline among people living with severe and enduring mental 
illness (SMI) has been significantly slower (1, 2). For example, in 
the USA, over the period 2004–2011, smoking among individuals 
with no mental illness declined from 19.5% to 15.6% (p < 0.001), 
compared with 28.8% to 27.0% (p = 0.006) among individuals 
living with mental illness (2). Smoking rates in people living with 
SMI have been found to be around double the general population 
and up to four times higher for those living with bipolar disorder 
or schizophrenia (1, 3, 4). Smoking increases the risk of a number 
of tobacco-related illnesses, including lung, throat and bowel 
cancers, stroke, chronic obstructive pulmonary disease (COPD), 
and myocardial infarction (5). Consequently, smoking is the 
leading cause of preventable death among people living with 
SMI—significantly shortening their life expectancy compared 
to the general population and accounting for almost half of all 
smoking-related deaths (4, 6–9).
Smoking-related conditions also cause significant morbidity 
and reduce the quality of life of affected people, with or without 
the presence of SMI (5, 10). Exacerbating this for people 
living with SMI, smoking has been associated with increased 
psychiatric symptoms and hospitalizations, as well as a 
requirement for higher psychiatric medication dosages because 
smoking accelerates the metabolism of some antidepressant and 
antipsychotic medications (11, 12).
Data on the economic burden associated with smoking 
in people with SMI are limited, but evidence suggests that it is 
significant. In Australia in 2007, it was estimated, that when 
compared to smokers without mental illness, the additional cost 
of health care, lost productivity, carer costs, cigarette expenditure, 
and other costs associated with observed heavier levels of smoking 
among ~1.25 million smokers with mental illness (not just SMI), 
was around AUD3.5 billion annually (or about AUD4.5 billion 
in 20181) (13). This is in addition to expected costs if smokers 
with mental illness smoked at similar levels to smokers with no 
mental illness—the main cost drivers being productivity losses 
(63%), health costs (12%), and cigarette expenditure (12%) (13). 
In the 2009/2010 UK financial year, it was estimated that the costs 
associated with smoking-related health care treatment, work-
related absenteeism, and premature mortality among people with 
SMI was £2.3 billion (or about £3 billion in 20182) (14).
Numerous smoking cessation strategies have been shown to be 
both effective and cost effective in the general population (15, 16). 
However, smokers with severe mental illness (SSMI) report lower 
cessation rates, in part attributable to higher levels of nicotine 
dependence, and they are likely to benefit from more intensive 
or extended interventions tailored to their needs (17). SSMI also 
report a lack of encouragement to quit by health professionals, 
who often mistakenly believe that people with mental illness 
are not interested in quitting and that it will interfere with their 
mental health recovery (12, 18).
Given the significant disease burden caused by smoking 
among people with SMI, improving access to smoking cessation 
interventions—and ensuring they are effective for SSMI—is 
1 Reserve Bank of Australia—https://www.rba.gov.au/calculator/annualDecimal.html.
2 Bank of England—https://www.bankofengland.co.uk/monetary-policy/inflation/
inflation-calculator
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a vital health priority for this target group. Telephone-based 
smoking cessation counseling services (such as quitlines) are 
helpful for many smokers, but SSMI are infrequently referred to 
such services by mental health practitioners as it is uncommon 
for smoking cessation to be included in mental health planning 
(19). This has led to the development of Quitlink—a randomized 
controlled trial (RCT) of peer worker facilitated quitline support 
for smokers with mental health problems, implemented in an 
Australian setting (20). It aims to coordinate and enhance the 
services of Quitline Victoria and engage mental health peer 
workers to bridge the persistent gap between mental health 
services and Quitline. The primary aim of the intervention is to 
help SSMI quit smoking. Secondary aims include assessment of 
the extent to which Quitlink improves health-related quality of 
life (HRQoL) and reduces the burden on the health care system 
in both the short and longer terms.
Examining the cost effectiveness of proven or potentially 
effective interventions is increasingly important for public sector 
funding decisions and priority setting (21, 22). Telephone-based 
counseling interventions with or without complementary nicotine 
replacement therapy (NRT) can be a relatively cost-effective way 
to achieve smoking abstinence in general populations in both 
upper and lower income country settings (16). Furthermore, 
modeling suggests such interventions may even be cost saving 
from a health care system perspective due to cost offsets resulting 
from prevented health costs in the future (23–26).
While it has been well established that telephone-based 
counseling interventions (with or without NRT) can be a very 
cost-effective strategy for improving health and extending lives 
(15, 16), there is little evidence regarding the cost effectiveness 
of any smoking cessation strategies specifically targeting SSMI 
(27). Barnett et al. (28) compared a cessation program (including 
psychological counseling, NRT, and bupropion) given in an 
outpatient care setting in the USA for smokers with depression 
measured against a brief care comparator. After 18  months, 
the intervention group had a 5.5% increased chance of ceasing 
smoking (p  <  0.05) at a cost of USD11,496 per successful quit 
and USD9,580 per life year gained, concluding that it was a 
relatively cost-effective intervention in the short run. In a more 
recent RCT, Barnett et al. (29) found a stage-based intervention 
(including computer-based assessment, regular feedback, face to 
face sessions, and up to 10 weeks of NRT) initiated with people 
during a psychiatric hospitalization, was highly cost effective. 
The intervention achieved around a 12 percentage point increase 
in smoking abstinence after 18 months compared with usual care 
[18.8% abstinence in the intervention arm versus 6.8% abstinence 
in usual care (p < 0.05)] at an estimated USD428 per additional 
quality adjusted life year (QALY) gained when modeled over the 
life course of participants. Rejas-Gutiérrez et al. (30) constructed 
a model to estimate the budgetary impact for the Spanish health 
care system from funding varenicline, bupropion, and NRT 
combined with medical follow-up and counseling for people 
with a major depressive disorder. They estimated that the cost of 
funding such interventions (€25.3 million) was offset by health 
costs avoided (€26.5 million) after 5 years, suggesting that cost 
offsets for the health care system might increase over a longer 
time period (30).
The Quitlink intervention will utilize existing and skilled 
Quitline and mental health peer workers. The peer workforce is 
developing in Australia and internationally, working alongside 
clinical staff to provide support based on shared lived experience 
of mental illness and recovery (31). In Australia, quitlines are 
government-funded services providing smoking cessation 
counseling across each state and territory. In addition, in the 
Australian setting, some of the medications to aid smoking 
cessation are currently subsidized. The presence of these 
funded health resources suggests that the additional resources 
required to implement Quitlink would be relatively modest. It is 
hypothesized then that, if effective, it is likely to be a highly cost-
effective intervention, which can feasibly be scaled up beyond 
the trial setting. Such a priori expectations make the case for 
a rigorous economic evaluation to be conducted alongside the 
Quitlink RCT. This paper presents a protocol for the economic 
evaluation of the Quitlink intervention to address the following 
research question:
From the Australian health care system and limited societal 
perspectives, what is the cost effectiveness of the Quitlink 
intervention to increase smoking cessation and QALYs among 
people living with SMI when compared with usual care?
THE QUITLINK TRIAL
Study Design
Quitlink is a cluster RCT, the design of which is described in 
detail in Baker et al. (20). In brief, a multicenter prospective, 
randomized, open, blinded endpoint design will be utilized to 
compare Quitlink against usual smoking care in helping SSMI to 
quit smoking. The trial aims to recruit 382 participants with SMI 
from participating residential and nonresidential, hospital, and 
community-based mental health services in Victoria, Australia. 
The trial will entail cluster randomization: where individuals 
are part of a short- or long-term residential rehabilitation 
program, that residential program will be considered a cluster. 
Where individuals are not part of a residential rehabilitation 
program, they will be randomized individually, i.e., a cluster 
of 1. Participants randomized to the intervention group will 
receive the full Quitlink intervention as described below. All 
participants will undergo follow-up at 2, 5, and 8  months 
postbaseline. The main outcomes are described below in the 
section Identification, Measurement, and Valuation of Outcomes 
and described in detail in Baker et al. (20). A qualitative study 
will investigate the experience of participants with a focus on 
further enhancing engagement with the intervention. Full ethics 
approval for the methods described here and in Baker et al. (20) 
was obtained from the University of Newcastle (H-2018-0192) 
and St Vincent’s Hospital, Melbourne (HREC/18/SVHM/154).
Screening, Randomization, and the Usual 
Care Control Group
Potential participants will be engaged and screened for 
eligibility by a trained mental health peer worker at specialist 
mental health services [see Baker et al. (20) for further details]. 
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For  eligible  persons, upon provision of informed consent, 
a baseline assessment will be undertaken. Following this, 
participants will receive a brief smoking cessation intervention 
consisting of brief advice and provision of Quit Victoria written 
materials that include the Quitline telephone number.
After the provision of this brief smoking cessation 
intervention, participants will be randomly allocated to the 
control group or the Quitlink intervention group. The control 
group will continue with usual care in relation to smoking 
cessation support, as provided by their health care team, that is, 
no further intervention will be provided by the research team.
The Intervention
Following randomization, those allocated to the intervention will 
be referred to an enhanced quitline call-back service for SSMI 
and have the option of receiving up to 8 weeks of NRT (patches, 
complemented by an oral form of NRT, to be used as per pack 
guidelines). Quitline will proactively contact the participant to 
offer up to 8 weeks of telephone smoking cessation counseling 
with a dedicated counselor, which will include monitoring of 
mental health symptoms, nicotine withdrawal symptoms, and 
medication side effects, as well as mood management strategies 
that aid cessation.
METHODS AND ANALYSIS
Economic Evaluation Overview
A cost-effectiveness evaluation will be conducted with 
incremental cost-effectiveness ratios (ICER) calculated for the 
cost (AUD) per person who quits and QALYs gained compared 
with usual care from both health care system and limited societal 
perspectives. Cost effectiveness will be estimated at 8  months 
postrandomization (trial-based evaluation with costs and 
outcomes as per the trial). Given that most of the anticipated 
benefits associated with smoking cessation will occur well beyond 
the trial period (15, 16, 24), downstream costs and benefits will 
be estimated via a modeled economic evaluation. Health care 
system costs and health and QALY benefits will be estimated over 
the life course of study participants and extrapolated to estimate 
the cost effectiveness of rolling out Quitlink nationally.
The health care system perspective will be of most relevance 
to agencies that are likely to fund scaleup beyond the trial 
setting. Data on important personal out-of-pocket impacts of 
Quitlink will also be collected and incorporated with the health 
care system data to construct the limited societal perspective 
analysis. In the Australian setting, cigarettes are highly taxed 
(to reduce smoking) and are among the most expensive in the 
world, while the population of people with SMI is generally 
financially disadvantaged and often marginalized economically 
(32, 33). This makes it important to also assess any consequent 
financial impacts on study participants as a result of receiving 
the Quitlink intervention.
Future costs and benefits will be discounted using an annual 
discount rate of 3% in the base-case. Furthermore, annual discount 
rates of 0 and 5% will be applied in sensitivity analysis to facilitate 
comparison with results from other economic evaluations of 
preventive health interventions, including smoking cessation 
interventions in people with SMI (25, 29, 34). To further aid decision-
makers, cost-effectiveness findings will be presented alongside 
descriptive assessments of the acceptability to stakeholders, 
feasibility of scaleup, sustainability, and equity implications of 
Quitlink implementation to be assessed by the research team in 
consultation with participating organizations (34, 35).
Trial-Based Economic Evaluation
Identification, Measurement, and Valuation 
of Outcomes
The clinical and HRQoL outcomes detailed below will be 
collected as part of participant assessments conducted at 
baseline, 2 months (= end of treatment), 5 months (= 3 months 
posttreatment), and 8 months (= 6 months posttreatment).
Health and Health-Related Behavioral Outcomes
The primary health outcome will be successful quits at 8 months 
postrandomization. A successful quit is defined as 6  months 
sustained abstinence, with no relapse of 7 or more days of 
continuous smoking, and no reported smoking in the past 
week with biochemical verification). Self-reported cigarette 
consumption will also be measured and for the purposes of the 
economic evaluation, used to assess changes in out of pocket 
expenditure associated with Quitlink.
Health-Related Quality of Life
Despite common beliefs that smoking cessation might worsen 
the mental health symptoms of smokers, some studies indicate 
that smoking cessation leads to no worsening and possibly 
improvement in mental health and psychological-related quality 
of life (36). It is also plausible that mood and mental well-being 
symptoms may change over time, e.g., deteriorate in the short 
term while quitting (e.g., first few weeks), and improve after that 
(e.g., months after successfully quitting) (36). To explore this, 
HRQoL data will be collected using the Assessment of Quality 
of Life-8 Dimension (AQoL-8D) instrument at baseline and 
follow-up observations at 2, 5, and 8 months. The AQoL-8D is a 
preference-based HRQoL instrument which enables calculation 
of QALYs experienced across the two study arms. Data from all 
time points will be plotted for both arms, and the difference in 
areas under the respective curves will be calculated. While the 
majority of benefit of this preventive intervention are expected 
in the future and a priori expectations of measurable change in 
HRQoL during the trial period are modest, among preference-
based HRQoL instruments, the AQoL-8D is considered relatively 
sensitive to changes in psychosocial dimensions of HRQoL 
(while also capturing important changes in other dimensions of 
HRQoL) (37). This means that it will be more likely to identify 
smaller changes in mental-health-related quality of life than 
other preference-based instruments.
Financial Stress
Respondents will be asked a short module of questions relating to 
their financial stress at baseline and follow-up observations (38). 
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For example, have they foregone meals; asked for financial help; 
or been unable to pay electricity, gas, or telephone bills because 
of a lack of money (see online Appendix to view questions)? 
This will provide further evidence for decision-makers and 
mental health and smoking program organizations regarding 
potential financial impacts of Quitlink on this financially 
disadvantaged population (32).
Identification and Measurement of Costs
Table 1 summarizes the costs included and the data collection 
strategy from both a health sector and societal perspective. Costs 
included from the health care system perspective will include 
direct intervention costs (e.g., opportunity cost of Quitline and 
peer worker staff, telephone calls, NRT) for both Quitlink and 
usual care, as well as drug and health service utilization costs. 
Pathway analysis will be undertaken to ensure all relevant 
costs are identified. These data will be collected from project 
administrative records, respondent surveys (baseline, 2, 5, and 
8  months) and with participant consent, linked data on their 
service and prescription medication use from the Australian 
Government subsidized Medicare (MBS) and Pharmaceutical 
Benefits (PBS) schemes, which are predominantly out-of-
hospital resource use.
Data on important out-of-pocket impacts of Quitlink will also 
be collected and incorporated with the health care system data 
to estimate costs from a limited societal perspective. These costs 
will include out-of-pocket co-payments associated with drug 
and health service utilization, expenditure on cigarettes, and 
cessation aids purchased in addition to those provided as part 
of the intervention, as well as time costs and productivity losses 
associated with absenteeism from paid and unpaid work and 
productive activities (see online Appendix to view questions).
Where data relies on respondent recall, for example, number 
of allied health visits or cigarettes smoked, the recall period 
will be deliberately kept relatively short (1  month and 1  week, 
respectively). Recall bias may remain an issue though, so the 
potential impact of this will be tested in sensitivity analyses (39). 
In general, a simple extrapolation rule will be followed where 
reported rates are applied for the full period since previous 
follow-up, where appropriately justified.
One-off costs for products which could be used in other 
settings, such as costs of developing the training and intervention 
materials, will be excluded. The costs and health implications 
from passive smoking will also be excluded.
Valuing Costs
All resource use will be costed using nationally published 
reference costs or market prices where appropriate. Personnel 
time (paid, unpaid, volunteer time) will be costed using 
opportunity cost principles, where volunteer/leisure time 
TABLE 1 | Costs included in trial-based cost-effectiveness analyses.
Cost category Costs Perspective Collection strategy 
Direct intervention costs Costs associated with training of peer workers 
and Quitline staff, including personnel time 
(facilitators and participants), venue/catering, 
printing/stationery.
HS & S Project administrative records.
Personnel time for intervention delivery: Quitline 
and peer worker support time spent per 
study participant in both Quitlink and usual 
care arms. Costs of telephone calls. Program 
management time.
On-costs will be included. 
HS & S Project administrative records and 
administrative data provided by 
participating organizations. 
Health service utilization Hospitalizations (including length of 
stay) and other intensive health services, 
including ED and community care units 
(CCUs) and prevention and recovery care 
services (PARCS). 
HS & S Respondent surveys.
Community-based (noninpatient) government 
subsidized health (including mental 
health) services. 
HS & S Linkage to Australian Department of Human 
Services data on Medicare and PBS use.
Literature review.
Allied health services (nonsubsidized) including 
(non-Quitline) counseling, acupuncture, 
hypnotherapy, group therapies. 
S Respondent surveys.
Nicotine replacement therapies and other 
quitting aids
e.g., patches, gum, lozenges, inhalator, 
sprays, e-cigarettes. 
HS & S Respondent surveys.
Medicines Including varenicline, bupropion, 
psychotropic medicines.
HS & S Australian Department of Human Services 
data on Medicare and PBS use,
literature review.
Cigarettes Cost of cigarette purchases. S Respondent surveys.
Productivity losses and gains Absenteeism from paid and unpaid work 
(e.g., volunteering, study, caring).
Potential increases in employment. 
S Respondent surveys.
Project records on session numbers 
and duration.
HS, Health care system; S, societal; ED, emergency department; PBS, Pharmaceutical Benefits Scheme.
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will be valued at 25% of appropriate average wage rates (34). 
Resource use of nonhealth sector goods and services will be 
valued at market prices and be informed by best available 
evidence from Australian-based studies. Where relevant, health 
resources will be costed as per the Manual of Resource Items 
for use in submissions to the Commonwealth of Australia’s 
Pharmaceutical Benefits Advisory Committee (40). Health 
care cost information will also be drawn from the Australian 
Institute of Health and Welfare (AIHW) health care cost data. 
All costs will be inflated to current Australian dollars for the 
year of study completion (2022) using the all-items Consumer 
Price Index from the Australian Bureau of Statistics.
Modeling Long-Term Cost Effectiveness
A decision analytic Markov model will be developed using 
TreeAge software to estimate the future benefits and cost 
savings arising from any increase in successful quits observed 
in the Quitlink arm. We will adapt and update the smoking 
cessation model developed with an Australian context by 
Hurley et al. (41). The model projects the future smoking status 
of the population where smoking status impacts on the risk of 
experiencing (progressing into the following health states)—
myocardial infarction (MI), stroke, COPD, or lung cancer. 
These four health states are known to have the largest disease, 
mortality, and health cost burden among smokers (41). For 
simplicity, the model does not include the potential for comorbid 
health states where a person may have more than one of these 
four states concurrently. Death following transition into one of 
these diagnosed health states can be caused by that condition 
or any other cause. “Healthy” smokers and ex-smokers can 
also die from other causes without experiencing these health 
states. This approach is intentionally conservative (i.e., it likely 
underestimates the benefits of quitting) and has been taken in a 
number of smoking models (24).
We plan to extend the Hurley and Matthews (41) model. 
Figure 1 depicts the potential health states that the modeled 
Quitlink cohort will face over repeat model annual cycles. 
Given smokers with SMI (compared to ex-smokers with SMI) 
face increased risk of hospitalization for a psychiatric episode, 
a psychiatric episodic health state will be added to the model to 
capture the costs related to hospitalizations and the impact on 
QALYs (12). QALY weights for the psychiatric episodic health 
state will be obtained where possible, from the literature or 
by expert opinion, guided by the AQoL-8D questionnaire. In 
the model, we will also consider that smoking cessation may 
reduce suicide risk—attempts and, more rarely, deaths (42, 
43). Uncertainty remains around this mechanism of action. 
However, the known links between smoking and reduced 
effectiveness of antipsychotic medication, and between 
smoking cessation and mood improvement, suggest that 
any increased smoking cessation achieved by Quitlink may 
plausibly reduce suicide attempts and deaths—especially if the 
program was scaled up. A review of the literature of the causal 
link between smoking and suicidality will be undertaken 
at the end of the trial period to determine the strength of 
evidence and suitability of including a suicidal health state 
in the Markov model and suicide as an additional smoking-
related cause of death.
The trial cohort at the end of the trial follow-up will enter 
the Markov model as either a healthy smoker or healthy 
ex-smoker (i.e., successful quitter), where “healthy” means 
they have not had a stroke, MI, or developed COPD or lung 
cancer. Their commencement QALY weight in the model 
will be their final observed QALY weight from the trial (i.e., 
8-month follow-up). Individuals will be modeled through 
annual cycles. In the first cycle, people have a probability of 
either remaining a healthy smoker or ex-smoker, relapsing 
from healthy ex-smoker to healthy smoker, experiencing a 
fatal or nonfatal MI, stroke, COPD, lung cancer, or entering 
a severe psychiatric episodic health state (e.g., psychiatric 
hospitalization and/or suicide attempt), or they may die from 
another cause.
Each health transition and health state incurs associated 
treatment/management costs. Associated health costs and risk of 
disease-related mortality can differ over time since initial episode/
diagnosis (41). The Markov cycles will continue until the entire 
cohort has either died or reached aged 85  years (41). The same 
model structure will be used to estimate the broader benefits and 
cost savings of scaling up Quitlink to a larger population cohort of 
people with SMI.
Existing evidence for transition probabilities for the 
different disease states and utility weights attached to life 
lived with those health states used in Hurley et al. (41) and 
Godfrey et al. (24) will be considered for use in this model, 
subject to an updated literature search. Smoking relapse rates 
will be estimated using the large longitudinal Household 
Income Labour Dynamics in Australia (HILDA) survey data. 
Specifically, relapse rates of data for people who self-report 
poor mental-health-related quality of life in the early HILDA 
waves on the included Short Form-12 item (SF-12) instrument 
will be analyzed.
The longer term health care system costs incurred by the 
two intervention arms will comprise actual health care resource 
usage obtained from the government subsidized MBS and PBS 
database (which will provide data of up to 4 years for the early 
study enrolments) and health care cost information from the 
Australian Institute of Health and Welfare (AIHW)—to estimate 
costs of acute and ongoing management associated with the 
stated main model health states. Where there is potential for 
double counting across the two data sources, conservative 
inclusion decisions will be made.
Where transition rate, utility weight, and health cost data 
are available specifically for people living with SMI (and if 
possible, in Australia), it will be used to populate the model. 
Given that most of such data are currently unavailable, data 
from general population studies will be employed, coupled 
with a discussion on how the likely cost effectiveness of 
Quitlink may be impacted. All model parameters will be 
subject to an updated literature search at the end-point of the 
clinical trial to identify if potentially more suitable model data 
have become available.
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Uncertainty and Scenario Analyses
All analyses in both the trial-based cost-efficacy and modeled 
cost-effectiveness evaluations will be subjected to both one-
way and probabilistic sensitivity analysis where the impacts 
of plausible variation in data parameters will be tested, using 
confidence intervals around for example, utility weights, and 
health costs associated with different health states. This will 
provide an understanding of which values or assumptions 
are associated with the greatest amount of uncertainty. As 
previously mentioned, by necessity, some model parameters 
will be populated with data from the general population, rather 
than specifically people with SMI. Given this, scenario analyses 
will be conducted to investigate the impact of SMI-related 
data adjustments, which expert opinion suggests is, prima 
facie appropriate, where there is only poor quality or no data 
available for a given parameter to test uncertainty. These will 
include, for example, different transition risks and lower utility 
scores attached to health states for people with SMI compared 
with general population data used, as well as uncertainty 
around treatment costs for the main modeled health states for 
people with SMI. These analyses will also enable estimates of 
the probability that Quitlink is cost effective to aid funding 
decision-makers in light of such model uncertainty.
Results of a number of sensitivity tests will be reported 
on a cost-effectiveness plane and as acceptability curves. The 
Australian Government has no explicit threshold for what it 
considers cost effective; however, there exists implicit evidence 
that the Pharmaceutical Benefits Advisory Committee view 
interventions that achieve an incremental cost effectiveness ratio 
(ICER) of no more than AUD45,000 per additional QALY gained, 
as cost effective (44). This threshold will be applied for the cost-
effective acceptability analysis. Published results will include 
a discussion of model validity, comparing results with those of 
other smoking cessation models including those reported in the 
literature review by (24).
DISCUSSION
This protocol sets out a plan to assess the cost effectiveness of 
Quitlink versus usual care via both trial-based and modeled 
economic evaluations. The publication of this protocol has two 
purposes. First, we aim to inform the research and broader public 
health communities of the conduct of this economic evaluation 
alongside the Quitlink trial. Second, we set out the plan for analyses 
a priori, thereby reducing potential biases made from ad hoc analytic 
decisions. Any deviations from this protocol will be described and 
justified in final analyses. In the event that no significant difference is 
found for the primary outcome, the described economic evaluation 
may be undertaken where there is a) significant change in key 
secondary outcomes (QALYs or number of cigarettes smoked) 
or b) compelling evidence suggesting the sample lacked power or 
insufficient follow-up to detect a likely significant difference. While 
we are setting out to identify and collect the best available data to 
establish the cost effectiveness of Quitlink, there are a number of 
potential limitations. The exclusion of so-called second-hand (or 
passive) smoking effects may result in an underestimation of the 
true benefits to the health care system and broader society as a 
result of any observed Quitlink treatment effect. For the trial-based 
evaluation, there is a risk of recall bias in the respondent surveys, 
relating to—among other data—health service use, medications 
used, NRTs, and cigarettes purchased. To minimize this potential 
bias, actual health and medication use data will be obtained from 
Australian Government MBS and PBS schemes. Further, in the 
FIGURE 1 | State transitions for Markov Model. COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; yr 1, first year in a given health state; 
yr > 1, subsequent years lived in a given health state.
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respondent surveys, the recall period that participants will be asked 
to consider will be deliberately kept short. A further potential risk 
to data reliability relates to HRQoL. While the AQoL-8D has been 
shown to be more sensitive to changes in people’s mental health 
than other instruments (37), there is a risk that the sample size and 
duration may be insufficient to identify the expected small changes 
in mental-health-related quality of life within the trial period.
The a priori expectation for benefits to largely occur well 
beyond the trial period (as has been largely demonstrated for 
smoking cessation interventions) justifies the decision to model 
future benefits and costs. However, the model-based analyses 
also carry a number of potential limitations. For the sake of 
transparency, a Markov model structure has been proposed that 
includes only a limited number of the full range of smoking-
related health states experienced by current and past smokers 
(24, 25) concentrating on the health and health system impacts 
of MI, stroke, COPD, lung cancer, and psychotic-related 
hospitalizations. While these conditions are responsible for an 
estimated 80% of the diseases and economic burden associated 
with smoking morbidity and mortality in the Australian setting, 
there are other smoking-related health issues which will not 
be included (41). Should Quitlink be found to be effective, the 
exclusion of other diseases from the model underestimates the 
true cost effectiveness of Quitlink. Furthermore, it is anticipated 
that much of the data for the smoking cessation modeling will 
come from the general population estimates; such data may not 
reflect the utilities or health costs or transition risks of people 
with SMI. An updated literature review for all parameters will be 
conducted at the end of the trial period to ensure up to date and 
relevant data is used for all model parameters.
Smoking places significant additional financial burden 
on people with SMI, a particularly financially vulnerable 
subpopulation. Any financial implications for people with SMI, 
seen through changes in cigarette consumption, out of pocket 
costs of health resource utilization and productivity will be 
presented, providing valuable information on the equity impacts 
of Quitlink. This research project will conduct analyses and 
present results of most relevance to smoking cessation program 
designers and health-funding decision makers. Quitlink has been 
designed for and will be trialed in a setting where Quitline and 
mental health peer workers are established parts of the health 
sector. The cost-effectiveness findings may not be generalizable 
to settings where such foundations for Quitlink are not in place.
CONCLUSION
The primary aim of this economic evaluation will be to 
establish the cost effectiveness of Quitlink. This protocol for the 
economic evaluation sets out a priori, the intended analyses to 
be undertaken. Any deviations from this plan that occur in the 
final publication of results will be clearly described and justified.
Smoking is a major cause of increased mortality and 
morbidity, as well as poorer mental-health-related quality of life 
and financial stress for people with SMI. The cost effectiveness 
of telephone-based smoking cessation interventions like Quitline 
(with and without NRT) has been well established in general 
populations; however, there is little evidence of cost effectiveness 
for such interventions that specifically target SSMI. Furthermore, 
evidence suggests that SSMI are less likely to be referred to 
quitlines. The Quitlink intervention, therefore, aims to bridge this 
gap. Quitlink utilizes existing mental health peer workforce to 
link SSMI with a tailored quitline service for SSMI. The research 
team hypothesizes that the use of these existing workforces and 
tailored quitline support for SSMI will result in Quitlink being 
found to be both effective and cost effective and also scalable.
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